CS-1170にかんする臨床的研究

DOI Web Site

書誌事項

タイトル別名
  • CLINICAL STUDIES ON CS-1170
  • CS 1170 ニ カンスル リンショウテキ ケンキュウ

この論文をさがす

抄録

CS-1170, a new semisynthetic cephamycin antibiotic, was studied on its antibacterial activity, absorption, excretion and clinical effect, and the following results were obtained.<BR>1) Antibacterial activity<BR>Susceptibility of CS-1170 was distributed among 0.39-100 ≤μg/ml with E. coli, and 45 of 50 strains were inhibited at 6.25 μg/ml or less: 0.78-100 ≤μg/ml with Klebsiella pneumoniae, and 41 of 50 strains were inhibited at 6.25 μg/ml or less: and 3.13-100 ≤μg/ml with Serratia marcescens. Antibacterial activity of CS-1170 was similar to cefazolin against gram-negative bacteria.<BR>2) Serum levels and urinary excretion<BR>CS-1170 was given by a single intravenous administration at a dose of 1.0 g in a case with normal renal, function, and serum level was 76.0 μg/ml after 15 minutes, 7.6 μg/ml after 4 hours, and serum half life of the drug was 1.1 hours. This serum half life was prolonged in proportion to the degree of impairment of renal function, and it was 9.3 hours in a case with 9.6 ml/min. of creatinine clearance. Urinary recovery of CS-1170 was 83.5% 6 hours after 1.0 g intravenous administration in a case with normal renal function, while it was only 26.1% in a case with 9.6 ml/min. of creatinine clearance.<BR>3) Clinical results<BR>CS-1170 was clinically applied to 10 cases of bacterial infection, including 7 cases of urinary tract infection and each 1 case of sepsis, cholecystitis and respiratory tract infection. The results obtained were good in 7 cases, fair in 1 case and poor in 2 cases.<BR>No marked side effects were observed with CS-1170.

収録刊行物

詳細情報 詳細情報について

問題の指摘

ページトップへ